Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells
- Kerstin Reimers†1Email author,
- Christine Radtke†1,
- Claudia Y Choi†1,
- Christina Allmeling1,
- Susanne Kall1,
- Paul Kiefer2,
- Thomas Muehlberger1 and
- Peter M Vogt1
© Reimers et al; licensee BioMed Central Ltd. 2009
Received: 25 July 2009
Accepted: 19 November 2009
Published: 19 November 2009
The objective of the present study was to evaluate the aptitude of TRAIL gene expression for inducing apoptosis in co-cultivated T-cells. This should allow preparing a strategy for the development of a durable, allogenic skin substitute based on the induction of an immune-privileged transplant. In order to counteract the significant potential of rejection in transplanted allogenic keratinocytes, we created a murine keratinocyte cell line which expressed TRAIL through stable gene transfer. The exogenic protein was localized on the cellular surface and was not found in soluble condition as sTRAIL. Contact to TRAIL expressing cells in co-culture induced cell death in sensitive Jurkat-cells, which was further intensified by lymphocyte activation. This cytotoxic effect is due to the induction of apoptosis. We therefore assume that the de-novo expression of TRAIL in keratinocytes can trigger apoptosis in activated lymphocytes and thus prevent the rejection of keratinocytes in allogenic, immune-privileged transplants.
Members of the TNF ligand family control and conduct numerous immunological and inflammation-related reactions. The Fas-FasL system and its associated mechanism of activation-induced cell death play an important role for the maintenance of hemostasis of the lymphoid system and the induction of immune tolerance . The TNF-related apoptosis-inducing ligand (TRAIL) was identified as a homologue of the Fas-ligand (FasL) . Yet, in contrast to FasL, TRAIL expression has been demonstrated in various tissues and organs [2–4], as the expression pattern of TRAIL receptors allows a subtle observation of apoptotic reactions. Until now, five different receptors for TRAIL have been described and all belong to the TNF receptor family. The receptors TRAIL-R1/DR4, TRAIL-R2/DR5, TRAIL-R3/DcR1 and TRAIL-R4/DcR2 exhibit a considerably homologous sequence of their extracellular domain and bind TRAIL as the only known ligand. The soluble receptor osteoprotegerin (OPG) belongs to a different sub-family and binds the ligand RANKL/OPGL as well. Following ligand binding and activation of cytoplasmatic death domains, TRAIL-R1 and TRAIL-R2 start series of signals for apoptosis [4, 5], whereas the decoy receptors do not transmit death signals. The ratio of expression of DR4/DR5 and decoy receptors by a tumor cell will determine its sensibility for TRAIL-induced apoptosis [2, 4]. An important function of TRAIL is the regulation of the immune response being involved in controlling the extent of the activated lymhocyte reaction . Interactions between TRAIL and lymphocytes can create so-called immune-privileged sites, e.g. the placenta .
The use of TRAIL for the induction of tolerance against allogenic transplants should be considered in burn medicine. The therapy of massive burn injuries is highly complex and can result in grave personal and socio-economic consequences. The therapeutic gold standard is the early resection of necrotic tissue and subsequent wound coverage with autologous skin transplants. Extensive burn injuries are associated with a lack of sufficient donor areas and the need for temporary allogenic or alloplastic coverage. However, allogenic transplants will ultimately be rejected, once the patient regained immunological competence. Allogenic keratinocytes exhibit a profound intrinsic immunogenicity due to the antigen-presenting properties of epidermal cells  which express MHC II and a host of inflammatory cytokines. The resulting rejection of the transplant is predominantly T-cell mediated, where even a small number of donor-specific T-cells can lead to the complete destruction of the transplanted skin . Experimental data show that skin allografts are rejected by either CD4+ or CD8+ T cells at any degree of antigenic mismatch . Consequently, the final wound coverage has to consist of autologous split-thickness skin grafts from repeatedly harvested donor sites. The prognosis of the patient can deteriorate due to rising numbers of surgical interventions, immunological reactions against the allotransplants, increasing danger of infection and inadequate wound healing of the donor areas. The production of autologous epidermal cells from full-thickness skin biopsies is hampered by long intervals of cultivation of up to three weeks. The long-term quality and stability of these keratinocyte sheets are inferior to alternative methods of coverage .
The development of a storable, cutaneous allo-transplant with a reduced immunogenic reactivity could help to solve most of these problems.
The aim of this study was to evaluate a concept for the induction of tolerance through the genetic transfer of TRAIL cDNA in keratinocytes to produce a localized lymphocytic apoptosis. We investigated whether the transfer of the TRAIL gene in cultivated keratinocytes could be cytotoxic for co-cultivated T-cells. Our results show that the constituitive expression of TRAIL after direct contact between effector and target cells will successfully trigger apoptosis in T-cells and thereby limit the transplant rejection. The use of keratinocytes expressing TRAIL could create an immune-privileged status for the successful transfer of allogenic keratinocytes as coverage of extensive burn wounds.
Materials and methods
The murine epithelial cell line JB6 (American Type Culture Collection, Manassas, VA) was cultured in MEM with 10% fetal calf serum (FCS), 2 mM Glutamine and 1% non-essential amino acids (Biochrom, Berlin, Germany) at 37°C and 5% CO2 in humidified atmosphere. The human T lymphoblastoma Jurkat cell line was maintained in RPMI supplemented with 10% FCS. For co-culture experiments JB6 cells were plated at a densitiy of 2,5 105/ml in six well tissue culture plates. Jurkat cells were either used untreated or stimulated for two days with ConA (1 μg/ml). Cells were washed and grown co-cultured for 48 hours in RPMI with 10% FCS.
Reagents Antibodies directed against the C-terminus of TRAIL were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) (clone: D-3) and BD Pharmingen (San Diego, CA) (clone: B5.1). Antibodies directed against the N-terminus of TRAIL were obtained from Chemicon (Temecula, CA). Antibodies directed against Caspase 8 were obtained from Santa Cruz Biotechnology. Secondary antibodies were purchased from Sigma (Taufkirchen, Germany) and Molecular Probes (Leiden, The Netherlands), respectively. Recombinant human TRAIL was obtained from Calbiochem (Schwalbach, Germany).
Generation of TRAIL producing cell clones
Full length TRAIL cDNA was cloned from a human lymphoma cDNA library (Lym12, Invitrogen, CA) using -ATG GCT ATG ATG GAG GTC- as 5' and -TTA GCC AAC TAA AAA GGC- as 3' primer, according to the published sequence (GeneBank accession number: U37518), and cloned into the expression vector pcDNA5/FRT (Invitrogen). For generating transfected cell lines JB6 pFRT/lac Zeo cells were transfected with the expression vector and pUG44 with the non-liposomal transfection reagent FuGene6 (Roche Molecular Biochemicals, Mannheim) following the supplier's instructions. Recombinant cells were selected with Hygromycin B (Calbiochem). β-galactosidase expression was measured by a specific ELISA obtained by Roche Molecular Biochemicals (Mannheim, Germany) and performed according to instructions and visualized by staining with 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal).
Cells were fixed in 4% Paraformaldehyde for twenty minutes at room temperature. Intracellular staining was achieved by treatment with 0.2% Triton-X-100. After blocking in 2% FCS/PBS cells were incubated with primary antibodies followed by secondary antibodies coupled to Alexa 488 or Alexa 546, respectively, at 37°C for 1 hour. Cells were covered with vector shield (Molecular probes) and examined by immunofluorescence microscopy.
Western Blot Analysis
Cells were harvested by centrifugation at 300 g, the pellet was resuspended in 100 μl RIPA buffer (10 mM Tris, pH8, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium desoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM phenylmethylsulfonyl fluoride, 4 μg/ml aprotinine, 1 mM sodium orthovanadate), sonicated and spun at 16600 g for 5 min to remove insoluble material. The protein content was determined by Bradford assay. Samples were mixed with Laemmli buffer and subjected to SDS-polyacrylamide gel electrophoresis followed by Western blotting to nitrocellulose membrane using standard techniques. Filters were blocked in 5% non-fat dried milk supplemented with 0.05% Tween 20. Immunodetection was performed either for 1 hour at room temperature or at 4°C over night with the antibodies of interest. NBT/BCIP (Roche) was used as a substrate to detect bound antibody.
Detection of cell death
FITC-Annexin V (Roche) staining was performed according to the manufacturer's instructions. After staining the cells were examined by immunofluorescence. Quantification of apoptotic cells was done with Apo-One assay (Promega) as recommended by the manufacturer. In brief, Jurkat cells were harvested from the co-cultures after 48 hours. 10000 cells were seeded into 96 well plates in RPMI medium. 100 μl substrate reagent was added and incubated at 37°C for one hour. Fluorescence was measured at 485 nm with a fluorescence reader (Genios, Tecan, Austria).
To quantify proliferation commercial kits (Cell titre blue, Promega) were used. 10000 Jurkat cells were seeded into 96 well plates. Substrate was added according to the manufacturer's instructions. Incubation was done at 37°C for one hour. The plates were read out at 590 nm.
ELISA To detect soluble TRAIL in cell culture medium ELISA (Biosource) was performed. Supernatants were collected from cells after 48 hours of cultivation. Adherent cells were lysed. Protein concentrations were determined using Bradford assay and normalised. Samples were added to precoated 96 well plates and ELISA was carried out as recommended by the manufacturer.
Data were collected from at least three independent experiments and are presented as the mean and SEM. The significance was determined by student's T test.
Generating a keratinocyte cell-line to express TRAIL
The present study investigated the capacity of overexpressed TRAIL to induce apoptosis in co-cultivated T-cells. In order to achieve higher reproducibility and standardization of results, we used stably transfected cells. A host cell line was established integrating a stable gene expression cassette with a lacZ-zeocin fusion gene. The hybrid gene was transcribed under the constitutive CMV promoter. However, the efficacy of the transcription may vary depending on the genomic insertion point of the integrated gene box. As a precaution, we used genetically identical cell clones to determine the rate of lacZ expression.
The lacZ-zeocin cassette flanked by FRT sites can be exchanged for another FRT flanked gene box, if a Flp recombinase derived from S. cerevisae is co-expressed. The insertion of the entire cDNA for TRAIl was intended. The complete open reading frame for TRAIL was amplified from a human B-cell lymphoma cDNA library with specific primers developed from the published sequence (Accession number: U37518). It was then cloned into the vector pcDNA5/FRT and checked by sequencing. The resulting expression vector was used to examine whether the recombinant expression of TRAIL in keratinocytes could trigger apoptosis in co-cultivated T-cells.
Transfected cells express TRAIL as a functional membrane protein
Immunofluorescence microscopy was conducted to show the localization of the gene products expressed (fig 2b). JB6pcDNA5/FRT TRAIL cells exhibited a strong membrane-bound fluorescence which, in contrast, was absent in the control groups of non-transfected or CAT transfected cells. The right orientation of the exogenous protein was confirmed by two different antibodies binding to the N-terminus and the C-terminus only. It showed the cytoplasmic N-terminus could only be detected when the cells were permeabilised with Triton-X-100 (fig 2b).
Jurkat cell co-cultivated with keratinocytes expressing TRAIL undergo increased cell death
TRAIL is cytotoxic for Jurkat cells through binding on the TRAIL receptor TRAIL R2/DR5. In order to demonstrate the functional activity of TRAIL expressed by the cell clone JB6, Jurkat cells sensitive to TRAIL  were placed in co-culture with the cell clone. The survival rate of the Jurkat cells was examined using an MTT proliferation assay. Apoptosis was measured using a fluorescent caspase substrat assay Apo-One (Promega). The percentage of dead Jurkat cells was calculated from three independent experiments.
Next, the Jurkat cells were stimulated with concanavaline A and placed in the co-cultures. Stimulation with ConA induces an increase of the endogenous expression of TRAIL in T cells  and also enhances the autocrine and paracrine sensitivity for apoptosis induced by TRAIL. For this purpose, the cells had been cultured in 1 μg/ml ConA enriched media for 2 days. The cells were then thoroughly washed and added to subconfluent JB6pcDNA5/FRT TRAIL or JB6pcDNA5/FRT CAT, respectively. We found an increase of the paracrine sensitivity for the membrane-bound TRAIL in epithelial cells lines.
Cell contact of TRAIL transfected keratinocytes and T cells leads to caspase activation and apoptotic cell death
Activation of apoptosis depends on the direct contact to TRAIL expressing keratinocytes
Further experiments were designed to determine the influence of direct cell contact of JB6pcDNA5/FRT TRAIL on Jurkat cells compared to the supernatant. The cell viability of Jurkat cells was measured by the conversion of resazurin to the fluorescent resurufin (fig 5b). This conversion depends directly on the viability of the cells. Jurkat cells obtained after 48 hrs from a co-culture with JB6pcDNA5/FRT TRAIL showed a decreased viability compared to the untreated control cells. Viability of cells maintained in the supernatant of JB6pcDNA5/FRT TRAIL cells was comparable to the controls.
TRAIL expressing keratinocytes induce apoptosis in native T cells
The transplantation of allogenic skin as a live saving therapy after massive burn injuries is an important issue for the application of immuno-modulating strategies. The utilization of apoptosis-inducing properties of some members of the TNF ligand family for the development of immune-privileged transplants is a fascinating, yet highly controversial means of allogenic transplantation. In a mixed lymphocyte-endothelial cell culture model, Cappellesso et al. showed that FasL transfected endothelial cells were effective in inducing apoptosis in Jurkat T cells. The authors conclude that expression of FasL in endothelial cells could be interesting to convey a death signal and induce hyporesponsiveness of allo reactive T cells for organ transplantation . The precise role of the FasL//Fas system for the so-called tumor counter attack has not been clarified yet [17–19]. Various data from in-vitro and in-vivo studies suggest an association between the expression of FasL, which is present in numerous tumours [20–23], and a significant localized reduction of tumor-infiltrating lymphocytes (TILs) secondary to apoptosis of sensitive T-cells [23, 25]. FasL acts in an analogous function to establish an immune-privileged status for special tissues, thereby protecting delicate organs like the eye against potential damage from immunological reactions . Similar findings were noticed for TRAIL, which shares numerous characteristics with FasL. The functional expression of TRAIL was demonstrated in human colon adenocarcinoma cell lines , possibly representing a biochemical mechanism of tumor escape in analogy to the FasL expression. FasL and TRAIL conjointly contribute to the immune-privileged status of the placenta . In order to evaluate the potential capability of TRAIL gene expression to induce tolerance through the initiation of apoptosis in a localized T cell population, we produced a keratinocyte clone expressing TRAIL which would trigger apoptosis in co-cultured Jurkat cells.
We showed how the stable transfection of a complete cDNA of TRAIL with a strong, constituitive promoter will lead to a lasting expression of membrane-bound, functional TRAIL on the cell surface of the transfected keratinocyte cell line. Jurkat cells are sensitive for the cytotoxicity mediated by TRAIL because of the expression of death-inducing receptors like TRAIL-R2/DR5 [2, 4]. Inoue et al. showed how apoptosis in Jurkat cells can be triggered by tumor cells using a TRAIL dependant signal pathway . In analogy to FasL, TRAIL can be expressed in many different tumor cells, ranging from breast- and braintumors to myeloid, lymphoid and colon carcinoma cells. Although the significance of FasL and TRAIL for the establishment of tumors has not been clarified in vivo, the induction of apoptosis represents an effective mechanism for the selective limitation of TILs, which can possibly be applied in transplants. The findings of our study show a pronounced cytotoxicity of complete TRAIL on TRAIL sensitive Jurkat cells and freshly isolated CD4+ and CD8+ cells. The cells will die due to a programmed cell death mediated by caspase. The cytotxic effect on Jurkat cells can be amplified by previous activation and incubation with ConA in a so-called activation induced cell death. The cell clone JB6pcDNA5/FRT TRAIL can induce apoptosis in T cells on direct contact and can thus effect a localized reduction of the total number of T cells.
There was no detectable secretion of sTRAIL in the cell culture media with the culturing conditions chosen in this study. The exposure of TRAIL sensitive Jurkat cells to the cell culture supernatant did not produce a cytotoxic effect, however, direct cell contact in the co-culture led to apoptosis in the target cells. An increase of the content of sTRAIL in humans can possibly produce hepatotoxicity and must be carefully considered before the application of specific gene therapy [28, 29]. Although TRAIL represents a type II transmembrane-protein, it can also exist in a soluble condition following processing and it will exhibit tumoricidal activity [15, 30, 31]. sTRAIL can mediate apoptotic signals into cells through interaction with the receptors TRAIL-R1/DR4 and TRAIL-R2/DR5. sTRAIL, however, is not as effective as membrane-bound TRAIL [32, 33], which is probably due to conformational differences [34, 35]. A gene-therapeutic strategy with foreign gene expression in the target cells should be considered as an alternative option in cancer therapy as well as for the induction of immunological tolerance in allogenic transplants.
Further studies using animal models are required to investigate if TRAIL expression in transplanted keratinocytes can induce immunological tolerance. The long-term effects of TRAIL expression on the inflammatory phase of wound healing as well as the interaction with other dermal cells are currently under investigation.
The work was supported by a grant of the Deutsche Forschungsgemeinschaft (DFG grant VO 508/3-1). We thank Sabrina Jahn and Andrea Lazaridis for excellent technical assistance.
- Bodmer JL, Schneider P, Tschopp J: The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002,27(1):19–26. 10.1016/S0968-0004(01)01995-8View Article
- Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995,3(6):673–682. 10.1016/1074-7613(95)90057-8View Article
- Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science 1997,276(5309):111–113. 10.1126/science.276.5309.111View Article
- Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996,271(22):12687–12690. 10.1074/jbc.271.22.12687View Article
- Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997,277(5327):818–821. 10.1126/science.277.5327.818View Article
- Jeremias I, Herr I, Boehler T, Debatin KM: TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol 1998,28(1):143–152. 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3View Article
- Phillips TA, Ni J, Pan G, Ruben SM, Wei YF, Pace JL, Hunt JS: TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege. J Immunol 1999,162(10):6053–6059.
- Sundstrom JB, Ansari AA: Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts. Transpl Immunol 1995,3(4):273–289. 10.1016/0966-3274(95)80013-1View Article
- Jones ND, Turvey SE, Van Maurik A, Hara M, Kingsley CI, Smith CH, Mellor AL, Morris PJ, Wood KJ: Differential susceptibility of heart, skin, and islet allografts to T cell-mediated rejection. J Immunol 2001,166(4):2824–2830.View Article
- Youssef AR, Otley C, Mathieson PW, Smith RM: Role of CD4+ and CD8+ T cells in murine skin and heart allograft rejection across different antigenic desparities. Transpl Immunol 2004,13(4):297–304. 10.1016/j.trim.2004.10.005View Article
- Woodley DT, Peterson HD, Herzog SR, Stricklin GP, Burgeson RE, Briggaman RA, Cronce DJ, O'Keefe EJ: Burn wounds resurfaced by cultured epidermal autografts show abnormal reconstitution of anchoring fibrils. JAMA 1988,259(17):2566–2571. 10.1001/jama.259.17.2566View Article
- Monleon I, Martinez-Lorenzo MJ, Monteagudo L, Lasierra P, Taules M, Iturralde M, Pineiro A, Larrad L, Alava MA, Naval J, Anel A: Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol 2001,167(12):6736–6744.View Article
- Mariani SM, Krammer PH: Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur J Immunol 1998,28(3):973–982. 10.1002/(SICI)1521-4141(199803)28:03<973::AID-IMMU973>3.0.CO;2-TView Article
- Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K, Yagita H: Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999,162(5):2639–2647.
- Griffith TS, Lynch DH: TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998,10(5):559–563. 10.1016/S0952-7915(98)80224-0View Article
- Cappellesso S, Thibault G, Hoarau C, Hérault O, Iochmann S, Bardos P, Lebranchu Y: FasL-transfected endothelial cells decrease the proliferative response of allogeneic PBL. Transpl Immunol 2002,10(4):293–302. 10.1016/S0966-3274(02)00073-4View Article
- Maher S, Toomey D, Condron C, Bouchier-Hayes D: Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002,80(2):131–137. 10.1046/j.1440-1711.2002.01068.xView Article
- O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F: Fas counter-attack-the best form of tumor defense? Nat Med 1999,5(3):267–268. 10.1038/6477View Article
- Restifo NP: Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000,6(5):493–495. 10.1038/74955PubMed CentralView Article
- Mann B, Gratchev A, Bohm C, Hanski ML, Foss HD, Demel G, Trojanek B, Schmidt-Wolf I, Stein H, Riecken EO, Buhr HJ, Hanski C: FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999,79(7–8):1262–1269. 10.1038/sj.bjc.6690202PubMed CentralView Article
- Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T: Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 2000,6(9):3560–3564.
- Shiraki K, Tsuji N, Shioda T, Isselbacher KJ, Takahashi H: Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 1997,94(12):6420–6425. 10.1073/pnas.94.12.6420PubMed CentralView Article
- Yoong KF, Afford SC, Randhawa S, Hubscher SG, Adams DH: Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion. Am J Pathol 1999,154(3):693–703.PubMed CentralView Article
- Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F: The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998,160(11):5669–5675.
- O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996,184(3):1075–1082. 10.1084/jem.184.3.1075View Article
- Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995,270(5239):1189–1192. 10.1126/science.270.5239.1189View Article
- Inoue H, Shiraki K, Yamanaka T, Ohmori S, Sakai T, Deguchi M, Okano H, Murata K, Sugimoto K, Nakano T: Functional expression of tumor necrosis factor-related apoptosis-inducing ligand in human colonic adenocarcinoma cells. Lab Invest 2002,82(9):1111–1119.View Article
- Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000,6(5):564–567. 10.1038/75045View Article
- Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, Deforge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001,7(4):383–385. 10.1038/86397View Article
- Mariani SM, Krammer PH: Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol 1998,28(5):1492–1498. 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-XView Article
- Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999,5(2):157–163. 10.1038/5517View Article
- Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, Bitzer M: Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003,63(10):2369–2372.
- Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, Moriyama M, Nakano T, Suzuki A: Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000,32(3):482–490. 10.1053/jhep.2000.16266View Article
- Bodmer JL, Meier P, Tschopp J, Schneider P: Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 2000,275(27):20632–20637. 10.1074/jbc.M909721199View Article
- Trabzuni D, Famulski KS, Ahmad M: Functional analysis of tumour necrosis factor-alpha-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem J 2000,350(Pt 2):505–510. 10.1042/0264-6021:3500505PubMed CentralView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.